U OF A PROFESSOR MICHAEL HOUGHTON RECEIVES NEW TITLE: NOBEL PRIZE WINNER!

Dr. Michael Houghton, Professor of Virology at the University of Alberta, and Director of the Li Ka Shing Applied Virology Institute (AVI), has another title to add to his impressive list of credentials: Nobel Laureate!

In October 2020, Houghton and two other scientists were named winners of the Nobel Prize in Physiology or Medicine for their past work in discovering the hepatitis C virus (HCV).

DR. MICHAEL HOUGHTON: FAST FACTS

  • Born and educated in England.
  • Received his PhD degree in 1977 from King’s College London.
  • Moved to California a few years after graduating with his PhD where he co-discovered the hepatitis C virus.
  • Relocated to University of Alberta in 2010.
  • Is a Professor of Virology at the University of Alberta where he is also Director of the Li Ka Shing Applied Virology Institute.
  • Completed a term as Canada Excellence Research Chair in Virology.
  • Has over 70 patents to his credit is listed as a co-inventor of 10 while at the University of Alberta.
  • Awarded Nobel Prize in October 2020.

A UNIQUE LAB OPTIMIZED FOR ACHIEVING CLINICAL APPLICATIONS

The University of Alberta’s Li Ka Shing Applied Virology Institute (AVI), gives researchers the expertise and the tools to quickly translate their research into clinical application.

AVI PROFESSORS AND RESEARCH TEAMS GETTING RESULTS

More than 24 professors and their researchers, under the leadership of Dr. Michael Houghton and Dr. Lorne Tyrrell, have been able to advance their work through the University of Alberta’s Li Ka Shing Applied Virology Institute (AVI).

LI KA SHING APPLIED VIROLOGY INSTITUTE ACHIEVEMENTS

  • World-leading HCV vaccine candidate designed, now being manufactured for clinical trials around the world.
  • Co-sponsoring clinical testing of a Group A Streptococcus vaccine in Alberta.
  • Planning Phase 1 clinical trial of a novel COVID-19 protease inhibitor.
  • Testing a novel COVID-19 vaccine in the lab.
  • Novel antivirals identified for cytomegalovirus (CMV).
  • Novel drugs designed computationally and chemically shown to be active in Alzheimer’s mouse model.
  • Computationally-derived drugs shown to be active in cellular models of non-alcoholic fatty liver disease.
  • Early-stage computationally-designed drugs targeting immune checkpoints for cancer therapy.

AVI MAKES ALBERTA A GLOBAL VIROLOGY RESEARCH LEADER

“The biggest drug companies in the world screen their drugs in what’s called a wet lab, and they will screen probably half a million drugs taking several months,” says Dr. Michael Houghton, Director of the Li Ka Shing Applied Virology Institute (AVI). “Computationally, we can now screen billions in just several weeks. I think we are ahead of big pharma in this regard, so we have this window of opportunity in Alberta.

“Hopefully we can be at the cutting edge of all that. We want to be able to tell Albertans that we’ve innovated medically though new drugs and vaccines,” says Dr. Houghton. “The AVI at the U of A is a unique place. It’s very exciting for me to be working here because we’ve got so many new opportunities to explore. It’s been the most stimulating phase of my career, here at the University to Alberta. It’s also been the hardest work I’ve ever done.”

U OF A PROFESSOR MICHAEL HOUGHTON RECEIVES NEW TITLE: NOBEL PRIZE WINNER!

Dr. Michael Houghton, Professor of Virology at the University of Alberta, and Director of the Li Ka Shing Applied Virology Institute (AVI), has another title to add to his impressive list of credentials: Nobel Laureate!

In October 2020, Houghton and two other scientists were named winners of the Nobel Prize in Physiology or Medicine for their past work in discovering the hepatitis C virus (HCV).

DR. MICHAEL HOUGHTON: FAST FACTS

  • Born and educated in England.
  • Received his PhD degree in 1977 from King’s College London.
  • Moved to California a few years after graduating with his PhD where he co-discovered the hepatitis C virus.
  • Relocated to University of Alberta in 2010.
  • Is a Professor of Virology at the University of Alberta where he is also Director of the Li Ka Shing Applied Virology Institute.
  • Completed a term as Canada Excellence Research Chair in Virology.
  • Has over 70 patents to his credit is listed as a co-inventor of 10 while at the University of Alberta.
  • Awarded Nobel Prize in October 2020.

A UNIQUE LAB OPTIMIZED FOR ACHIEVING CLINICAL APPLICATIONS

The University of Alberta’s Li Ka Shing Applied Virology Institute (AVI), gives researchers the expertise and the tools to quickly translate their research into clinical application.

AVI PROFESSORS AND RESEARCH TEAMS GETTING RESULTS

More than 24 professors and their researchers, under the leadership of Dr. Michael Houghton and Dr. Lorne Tyrrell, have been able to advance their work through the University of Alberta’s Li Ka Shing Applied Virology Institute (AVI).

LI KA SHING APPLIED VIROLOGY INSTITUTE ACHIEVEMENTS

  • World-leading HCV vaccine candidate designed, now being manufactured for clinical trials around the world.
  • Co-sponsoring clinical testing of a Group A Streptococcus vaccine in Alberta.
  • Planning Phase 1 clinical trial of a novel COVID-19 protease inhibitor.
  • Testing a novel COVID-19 vaccine in the lab.
  • Novel antivirals identified for cytomegalovirus (CMV).
  • Novel drugs designed computationally and chemically shown to be active in Alzheimer’s mouse model.
  • Computationally-derived drugs shown to be active in cellular models of non-alcoholic fatty liver disease.
  • Early-stage computationally-designed drugs targeting immune checkpoints for cancer therapy.

AVI MAKES ALBERTA A GLOBAL VIROLOGY RESEARCH LEADER

“The biggest drug companies in the world screen their drugs in what’s called a wet lab, and they will screen probably half a million drugs taking several months,” says Dr. Michael Houghton, Director of the Li Ka Shing Applied Virology Institute (AVI). “Computationally, we can now screen billions in just several weeks. I think we are ahead of big pharma in this regard, so we have this window of opportunity in Alberta.

“Hopefully we can be at the cutting edge of all that. We want to be able to tell Albertans that we’ve innovated medically though new drugs and vaccines,” says Dr. Houghton. “The AVI at the U of A is a unique place. It’s very exciting for me to be working here because we’ve got so many new opportunities to explore. It’s been the most stimulating phase of my career, here at the University to Alberta. It’s also been the hardest work I’ve ever done.”

U OF A PROFESSOR MICHAEL HOUGHTON RECEIVES NEW TITLE: NOBEL PRIZE WINNER!

Dr. Michael Houghton, Professor of Virology at the University of Alberta, and Director of the Li Ka Shing Applied Virology Institute (AVI), has another title to add to his impressive list of credentials: Nobel Laureate!

In October 2020, Houghton and two other scientists were named winners of the Nobel Prize in Physiology or Medicine for their past work in discovering the hepatitis C virus (HCV).

DR. MICHAEL HOUGHTON: FAST FACTS

  • Born and educated in England.
  • Received his PhD degree in 1977 from King’s College London.
  • Moved to California a few years after graduating with his PhD where he co-discovered the hepatitis C virus.
  • Relocated to University of Alberta in 2010.
  • Is a Professor of Virology at the University of Alberta where he is also Director of the Li Ka Shing Applied Virology Institute.
  • Completed a term as Canada Excellence Research Chair in Virology.
  • Has over 70 patents to his credit is listed as a co-inventor of 10 while at the University of Alberta.
  • Awarded Nobel Prize in October 2020.

A UNIQUE LAB OPTIMIZED FOR ACHIEVING CLINICAL APPLICATIONS

The University of Alberta’s Li Ka Shing Applied Virology Institute (AVI), gives researchers the expertise and the tools to quickly translate their research into clinical application.

AVI PROFESSORS AND RESEARCH TEAMS GETTING RESULTS

More than 24 professors and their researchers, under the leadership of Dr. Michael Houghton and Dr. Lorne Tyrrell, have been able to advance their work through the University of Alberta’s Li Ka Shing Applied Virology Institute (AVI).

LI KA SHING APPLIED VIROLOGY INSTITUTE ACHIEVEMENTS

  • World-leading HCV vaccine candidate designed, now being manufactured for clinical trials around the world.
  • Co-sponsoring clinical testing of a Group A Streptococcus vaccine in Alberta.
  • Planning Phase 1 clinical trial of a novel COVID-19 protease inhibitor.
  • Testing a novel COVID-19 vaccine in the lab.
  • Novel antivirals identified for cytomegalovirus (CMV).
  • Novel drugs designed computationally and chemically shown to be active in Alzheimer’s mouse model.
  • Computationally-derived drugs shown to be active in cellular models of non-alcoholic fatty liver disease.
  • Early-stage computationally-designed drugs targeting immune checkpoints for cancer therapy.

AVI MAKES ALBERTA A GLOBAL VIROLOGY RESEARCH LEADER

“The biggest drug companies in the world screen their drugs in what’s called a wet lab, and they will screen probably half a million drugs taking several months,” says Dr. Michael Houghton, Director of the Li Ka Shing Applied Virology Institute (AVI). “Computationally, we can now screen billions in just several weeks. I think we are ahead of big pharma in this regard, so we have this window of opportunity in Alberta.

“Hopefully we can be at the cutting edge of all that. We want to be able to tell Albertans that we’ve innovated medically though new drugs and vaccines,” says Dr. Houghton. “The AVI at the U of A is a unique place. It’s very exciting for me to be working here because we’ve got so many new opportunities to explore. It’s been the most stimulating phase of my career, here at the University to Alberta. It’s also been the hardest work I’ve ever done.”